Print

Arbor Pharmaceuticals Release: New Hospitalization Data from the African-American Heart Failure Trial to be Presented at the American College of Cardiology's 2012 Scientific Session  
3/27/2012 9:01:04 AM

ATLANTA, March 26, 2012 /PRNewswire/ -- Arbor Pharmaceuticals, a specialty pharmaceutical company based in Atlanta, GA, announced today that Dr. Inder Anand, MD will present new hospitalization data from the landmark African-American Heart Failure Trial (A-HeFT) at the 2012 American College of Cardiology Scientific Session in Chicago, Illinois on March 26, 2012.

The A-Heft Trial, entitled, "Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure" was published in the New England Journal of Medicine in November 2004. The A-HeFT trial reported landmark outcomes of reduced mortality, reduced time to first hospitalization and improvement in functional status in black heart failure patients when the fixed-dosed combination of isosorbide dinitrate and hydralazine was added to the current course of standard therapy for the treatment of heart failure.

These outcomes led to the early termination of the A-HeFT trial and a subsequent update to the 2009 American College of Cardiology Foundation and American Heart Association treatment guidelines for heart failure.

The fixed-dose combination of isosorbide dinitrate and hydralazine is marketed by Arbor Pharmaceuticals under the brand name of BiDilĀ®.

BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure and to improve patient-reported functional status.

See full Prescribing Information at www.bidil.com

About Arbor Pharmaceuticals, Inc.
Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused on the cardiovascular and pediatric markets. The company intends to become a leading specialty pharmaceutical company by actively licensing, developing and commercializing late-stage products for specialty focused conditions. Arbor currently markets multiple NDA and ANDA approved products with several more in development.

For more information regarding Arbor Pharmaceuticals, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.

SOURCE Arbor Pharmaceuticals, Inc.


//-->